<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BEBULIN- coagulation factor ix human 
			 </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>BEBULIN <br>(Factor IX Complex),<br>Nanofiltered and Vapor Heated<br>Lyophilized
        Powder for Reconstitution for Intravenous Administration </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_84478547-fb83-4b49-b432-dbebe9689e62"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">BEBULIN (Factor IX Complex), Nanofiltered and Vapor Heated is a
                            purified, sterile, freeze-dried concentrate of the Coagulation Factor IX
                            (Christmas Factor) as well as Factor II (<span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span>) and Factor
                            X (Stuart-Prower Factor) and low amounts of Factor VII. In addition, the
                            product contains small amounts of heparin (≤ 0.15 IU heparin per IU
                            Factor IX).</p>
<p>BEBULIN is standardized in terms of Factor IX content and each
                            vial is labeled for the Factor IX content indicated in International
                            Units (IU). One International Unit of Factor IX (according to the
                            current International Standard for Human Blood Coagulation Factors II,
                            IX, and X in concentrates) corresponds to the activity of Factor IX in 1
                            mL of fresh normal human plasma.</p>
<p>BEBULIN is manufactured from large plasma pools of human plasma.
                            Screening against potentially infectious agents begins with the donor
                            selection process and continues throughout plasma collection and plasma
                            preparation. Each individual plasma donation used in the manufacture of
                            BEBULIN is collected only at FDA approved blood establishments and is
                            tested by FDA licensed serological tests for <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">Hepatitis B Surface Antigen</span>
                            (HBsAg), for antibodies to Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV-1/HIV-2)
                            and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus (HCV) in accordance with U.S. regulatory
                            requirements. As an additional safety measure, mini-pools of the plasma
                            are tested for the presence of HIV-1 and HCV by FDA licensed Nucleic
                            Acid Testing (NAT) and found negative. Validated virus
                            removal/inactivation steps have been integrated into the manufacturing
                            process, namely 35 nm nanofiltration<span class="Sup">1</span> and a vapor heat
                            treatment process<span class="Sup">2</span> [10 hours at 60°C and subsequent 1 hour at
                            80°C under the condition of 7-8% (w/v) residual moisture]<span class="Bold">. </span>In addition DEAE-Sephadex adsorption
                            contributes to the virus safety profile of BEBULIN. Despite these
                            measures, this product can still potentially transmit
                                disease<span class="Sup">3</span> [see <span class="Italics"><a href="#i4i_warnings_id_fc6ca0e5-6e50-4f62-9ddf-95d16a599913">Warnings</a></span>].</p>
<p><span class="Italics">In vitro </span>spiking studies
                            have been used to validate the capability of the manufacturing process
                            to remove and inactivate viruses. To establish virus clearance capacity
                            of the manufacturing process, these virus clearance studies were
                            performed in accordance with good laboratory practices under extreme
                            conditions (e.g. at minimum incubation times and temperatures below
                            specifications for vapor-heat treatment). The <span class="Italics">in vitro</span> viral reduction studies
                            performed on nanofiltered BEBULIN are summarized in <a href="#id_1b03d8be-ae38-4758-8cad-0dd4d7dec772">Table 1
                            </a>.</p>
<a name="id_1b03d8be-ae38-4758-8cad-0dd4d7dec772"></a><table border="single" width="477">
<caption><span>Table 1 Mean
                                    log<span class="Sub">10</span> Reduction Factors (RFs) For Each Virus and
                                Manufacturing Step<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>   </span></caption>
<col width="17.2%">
<col width="15.1%">
<col width="14.9%">
<col width="17.2%">
<col width="18.4%">
<col width="17.2%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Reduction factors
                                    &lt; 1 log are not used for calculation of the overall reduction
                                    factor.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Studies
                                                on B19V, which are considered experimental in
                                                nature, have demonstrated a virus reduction factor
                                                of not more than 3.6 log<span class="Sub">10 </span>and 4.6
                                                  log<span class="Sub">10</span> by DEAE-Sephadex adsorption and
                                                vapor -heat treatment,
                                            respectively.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>HIV-1,
                                                Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus Type 1<br>BVDV, Bovine
                                                Viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Virus (model for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus
                                                and other lipid enveloped RNA viruses)<br>PRV,
                                                Pseudorabies Virus (model for lipid enveloped DNA
                                                viruses including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus)<br>HAV,
                                                <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Virus <br>MMV, Mice Minute Virus (model
                                                for non-lipid enveloped DNA viruses, including human
                                                parvovirus B19 [B19V])</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>n.d.: Not
                                            done</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Studies on
                                            West Nile Virus (WNV), have demonstrated a virus
                                            reduction factor of 3.1 log<span class="Sub">10 </span>by the 35 nm
                                            nanofiltration step.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Virus Type</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Enveloped RNA</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Enveloped DNA</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Non-enveloped RNA</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Non-enveloped DNA</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Virus Family</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Retroviridae</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Flaviviridae</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Herpesviridae</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Picornaviridae</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Parvoviridae<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Virus<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">HIV-1</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">BVDV</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">PRV</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">HAV</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">MMV</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">DEAE Sephadex Adsorption</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d</td>
<td class="Botrule Rrule" align="center" valign="middle">1.4</td>
<td class="Botrule Rrule" align="center" valign="middle">1.3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">35
                                        nm Nanofiltration<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt; 6.4</td>
<td class="Botrule Rrule" align="center" valign="middle">2.0</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt; 6.0</td>
<td class="Botrule Rrule" align="center" valign="middle">1.7</td>
<td class="Botrule Rrule" align="center" valign="middle">≤1.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Vapor-Heat Treatment</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt; 6.8</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt; 7.1 </td>
<td class="Botrule Rrule" align="center" valign="middle">&gt; 7.4</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt; 4.5</td>
<td class="Botrule Rrule" align="center" valign="middle">≤1.0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Overall log reduction factor (ORF)</td>
<td class="Rrule" align="center" valign="middle">&gt;
                                        13.2</td>
<td class="Rrule" align="center" valign="middle">&gt;
                                        9.1</td>
<td class="Rrule" align="center" valign="middle">&gt;
                                        13.4</td>
<td class="Rrule" align="center" valign="middle">&gt;
                                        7.6</td>
<td class="Botrule Rrule" align="center" valign="middle">1.3</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_505220ae-fbdb-4294-86d4-3b59c868d4df"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">BEBULIN is a combination of vitamin K-dependent clotting factors
                            (Factor IX, II, X) and found in normal plasma. The administration of
                            BEBULIN provides an increase in plasma levels of Factor IX and can
                            temporarily correct the coagulation defect of patients with Factor IX
                            deficiency. Plasma levels of Factors II and X will also be increased.
                            However, no clinical studies have been conducted to show benefit from
                            this product for treating deficiencies other than Factor IX
                            deficiency.</p>
<p><span class="Italics">In vivo</span> recovery of BEBULIN was
                            determined using the former International Standard, WHO 72/32 and was
                            found to be 53.3% ±9.6%, 57.5% ±21.8%, and 53.24% ±16.95%, respectively.
                            In the same studies, using different methodologies, half-lives were
                            determined to be 19.4 hrs ±3.8 hrs, 24.6 hrs ±3.2 hrs, and 19.97 hrs
                            ±8.24 hrs, respectively<span class="Sup">1</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_fa69a546-8231-4b33-a911-f8d79e16fa1f"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">BEBULIN is indicated for the prevention and control of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                            episodes in adult patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> B (congenital Factor IX
                            deficiency or Christmas disease).</p>
<p>BEBULIN is not indicated for use in the treatment of Factor VII
                            deficiency. No clinical studies have been conducted to show benefit from
                            this product for treating deficiencies other than Factor IX
                            deficiency.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6411bf70-ac71-46f7-b175-9712ae746079"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">BEBULIN is contraindicated in patients with</p>
<ul>
<li>Known history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to the product</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to heparin</li>
<li>Known history of <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_fc6ca0e5-6e50-4f62-9ddf-95d16a599913"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_115fed7e-b3a8-4e1b-8ba9-ece4dc5620f9"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic events</span> (<span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, pulmonary
                                    <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>, <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic stroke</span>) as well as disseminated
                                    intravascular coagulation (DIC) have been reported with BEBULIN.
                                    The risk of thromboembolic complications including DIC and
                                    hyperfibrinolysis is higher in patients with congenital or
                                    acquired <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span>, with repeated dosing or high
                                    doses of BEBULIN. Because of the risk of thromboembolic
                                    complications, closely monitor patients when administering
                                    BEBULIN: </p>
<ul>
<li>Monitor patients closely for signs and symptoms of
                                        intravascular coagulation or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. </li>
<li>Monitor Factor IX level in patients predisposed to
                                        thromboembolic complications including patients with a
                                        history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, patients with liver
                                        disease, pre- or postoperative patients, and
                                        neonates.</li>
<li>Stop the infusion immediately and initiate appropriate
                                        diagnostic and therapeutic measures at the first signs or
                                        symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_c5857839-f280-4449-befc-ea5af2ef54ca"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including
                                    anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported with
                                    BEBULIN. Manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or allergic
                                    reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>,
                                    <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>,
                                    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In the
                                    event of an anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, stop the
                                    infusion immediately and administer appropriate emergency
                                    treatment. Evaluate patients experiencing <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> for
                                    the presence of an inhibitor.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_5353f910-4fc9-45f9-bd77-a07ca0dbb3f5"></a><a name="section-5.3"></a><p></p>
<h2>Development of Inhibitor</h2>
<p class="First">Formation of circulating antibodies inhibiting Factor IX
                                    has been reported with the administration of BEBULIN. If such an
                                    inhibitor occurs, the condition will manifest itself as a poor
                                    clinical response. <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic syndrome</span> has been reported
                                    following attempted immune tolerance induction in <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> B
                                    with Factor IX inhibitor receiving factor IX products including
                                        BEBULIN.<span class="Sup">4</span> The safety and efficacy of using factor
                                    IX products including BEBULIN for immune tolerance induction
                                    have not been established. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_75e01775-f1eb-4362-8033-9aa4314338cd"></a><a name="section-5.4"></a><p></p>
<h2>Transmission of Infectious Agents</h2>
<p class="First">Because BEBULIN is made from human plasma, it may carry a
                                    risk of transmitting infectious agents, e.g., viruses, the
                                    variant Creutzfeldt-Jakob disease (vCJD) agent, and
                                    theoretically, the classic Creutzfeldt-Jakob disease agent. This
                                    also applies to unknown or emerging viruses and other pathogens.
                                    No cases of transmission of viral diseases or vCJD have been
                                    associated with BEBULIN. </p>
<p>ALL <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician to possibly have
                                    been transmitted by this product should be reported by the
                                    physician or other healthcare provider to Baxter Healthcare
                                    Corporation, at 1-800-423-2862 (in the U.S.).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_b874dd33-30af-488d-8d49-f97b326ed360"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_c37c11cd-4876-4a8a-9620-21e131cb8f3a"></a><a name="section-6.1"></a><p></p>
<h2>Interference with Heparin Sensitivity Laboratory Testing </h2>
<p class="First">BEBULIN contains heparin. Take heparin content into
                                    account when performing clotting tests sensitive to
                                    heparin.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_fdb3acef-0131-4aa4-bb21-946499f00c5a"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Inform patients of all signs and symptoms of immediate
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>/<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>,
                                    <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">retching</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>/<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span> or other
                                    body areas, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>,
                                    <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>,
                                    or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. Advise patients to discontinue use of
                                    the product and contact their physician if these symptoms occur
                                    and seek emergency care immediately for serious
                                    symptoms.</p>
<p>Inform patients of all signs and symptoms of parvovirus
                                    B19 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, which is especially serious in pregnant women or
                                    immune-compromised individuals. Symptoms of parvovirus B19
                                    <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>
                                    followed about two weeks later by a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>.
                                </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_11368a21-2919-4802-a3e9-12e7d97b4474"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">No drug interaction studies were performed. The effect of
                                    vitamin K antagonists (e.g. warfarin) can be temporarily
                                    overcome by the administration of human <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> complex
                                    products, including BEBULIN, which provides increased plasma
                                    levels of functional vitamin-K dependent coagulation Factors
                                    (II, IX and X)<span class="Sup">6</span>. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_7099517a-2242-410c-ae0e-6e1eff6937fc"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy Category C - Animal reproduction studies have
                                    not been conducted with BEBULIN. It is also not known whether
                                    BEBULIN can cause fetal harm when administered to a pregnant
                                    woman or can affect reproduction capacity.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d55ef261-ad48-4bca-8127-6c7857da1d60"></a><a name="section-6.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and efficacy of the use of BEBULIN in
                                    pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f497a589-12f4-4891-ba87-054467e835c5"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6ed4c8cb-939b-4b23-9d67-7ca8357675ac"></a><a name="section-7.1"></a><p></p>
<h2>Clinical Trial Experience</h2>
<p class="First"><span class="Italics">Because clinical trials are
                                        conducted under widely varying conditions, adverse reaction
                                        rates observed in the clinical trials of a drug cannot be
                                        directly compared to rates in the clinical trials of another
                                        drug and may not reflect the rates observed in clinical
                                        practice.</span></p>
<p>The following adverse reactions were reported in clinical
                                    studies with a previous formulation of BEBULIN:</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, and
                                    <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>.</p>
<p>The formation of inhibitor antibodies to Factor IX has
                                    been observed with the administration of BEBULIN.
                                    <br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b758d2d5-a08a-4d94-b28a-bfd37b5a3ac0"></a><a name="section-7.2"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First"><span class="Italics">Because postmarketing reporting of
                                        adverse reactions is voluntary and from a population of
                                        uncertain size, it is not always possible to reliably
                                        estimate the frequency of these reactions or establish a
                                        causal relationship to product exposure.</span></p>
<p><a href="#id_95e7c8ad-575d-46c2-8793-0731ba9fe844">Table 2</a> lists the adverse reactions reported
                                    during postmarketing use of BEBULIN.</p>
<a name="id_95e7c8ad-575d-46c2-8793-0731ba9fe844"></a><table border="none" width="479">
<caption><span>Table 2
                                        Postmarketing Adverse Reactions</span></caption>
<col width="45.3%">
<col width="54.7%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold">Blood and Lymphatic System
                                                  Disorders</span></td>
<td align="left" valign="top"><p class="First">Disseminated intravascular
                                                  coagulation</p></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Immune System
                                                  Disorders</span></td>
<td align="left" valign="top">
<p class="First">Anaphylactic/Anaphylactoid
                                                  reactions,</p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Nervous System
                                                  Disorders</span></td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Cardiac
                                                  Disorders</span></td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Vascular
                                                  Disorders</span></td>
<td align="left" valign="top">
<p class="First">Thromboembolic
                                                  events (including Deep vein</p><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>,
                                                <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">Thrombotic stroke</span>),
                                                <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Respiratory, Thoracic, and
                                                  <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span>,
                                                  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Gastrointestinal
                                                  Disorders</span></td>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Skin and Subcutaneous
                                                  Tissue Disorders</span></td>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, Facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>,
                                                  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Renal and Urinary
                                                  Disorders</span></td>
<td align="left" valign="top">
<p class="First">Nephrotic
                                                  syndrome (following attempted</p>immune
                                                tolerance induction)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="Bold">General Disorders and
                                                  Administration Site Conditions</span></td>
<td align="left" valign="top">Infusion site reactions,
                                                including Infusion site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
</tr>
</tbody>
</table>
<p>In addition to reactions listed above, myocardial
                                    <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> has been identified in the published literature with
                                    other Factor IX products.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_ef7c8cae-675f-43c2-aa47-cf9900be09ce"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravenous administration only</span></p>
<p>One International Unit (IU) of Factor IX activity/kg will
                            increase the plasma level of Factor IX by 0.8%. Accordingly, the
                            following formula is provided for dosage calculations:</p>
<p>Number of Factor IX IU required = bodyweight (kg) x desired
                            Factor IX increase (% of normal) x 1.2.</p>
<p>The response to treatment will vary from patient to patient.
                            Exact dosage determination should be based on localization and extent of
                            <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and the level of Factor IX to be achieved. Close laboratory
                            monitoring of the Factor IX level is required to determine proper
                            dosage, particularly with severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and major surgery. Larger
                            doses than those derived from the above formula may be required;
                            particularly if treatment is delayed. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0a9506c-58c3-4189-876a-b33105556912"></a><a name="section-8.1"></a><p></p>
<h2>Management of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Sup">7-11</span>
</h2>
<p class="First">Approximate desired Factor IX levels, typical initial
                                    doses, and the average duration of treatment are suggested in
                                        <a href="#id_233ef4a8-423f-4263-a46c-a276e3e0ad46">Table 3</a>. For minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, a single dose will
                                    usually be sufficient; otherwise a second dose may be given
                                    after 24 hours. More severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> will require several
                                    doses at approximately 24-hours intervals. For maintenance
                                    therapy, usually two thirds of the initial dose is
                                    infused.</p>
<a name="id_233ef4a8-423f-4263-a46c-a276e3e0ad46"></a><table border="single" width="424">
<caption><span>Table 3
                                        Management of Specific Types of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></caption>
<col width="27.1%">
<col width="29.0%">
<col width="21.5%">
<col width="22.4%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>For
                                                  patients predisposing to <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> see <span class="Italics">Precautions</span>
                                                  section.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Approximate</span><span class="Bold">Desired Factor IX
                                                  Level</span></p>
<span class="Bold">(% Normal)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Typical
                                                  Initial</span><span class="Bold">Dose</span></p>
<span class="Bold">(International
                                                  Units/kg)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Average
                                                  Duration</span><span class="Bold">of Treatment </span></p>
<span class="Bold">(Days)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Minor</span><br>Early <span class="product-label-link" type="condition" conceptid="76784" conceptname="Hemarthrosis">hemarthrosis</span>,<br>minor
                                                  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>,</p>and <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span>, mild
                                                <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span></td>
<td class="Botrule Rrule" align="center" valign="middle">20</td>
<td class="Botrule Rrule" align="center" valign="middle">25-35</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Moderate</span><br>Severe joint <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>,
                                                  <br>early <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, major open <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, minor
                                                  <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, minor
                                                <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>,</p><span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>,<br>and
                                                <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>,<br>major <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span></td>
<td class="Botrule Rrule" align="center" valign="middle">40</td>
<td class="Botrule Rrule" align="center" valign="middle">50-65</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">2 or until
                                                  adequate</p> <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Major</span><span class="Bold"><br></span>Severe <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> major <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>,
                                                  Severe <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>,</p><span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, and
                                                <br><span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span></td>
<td class="Rrule" align="center" valign="middle">≥60<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center" valign="middle">75-90</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">2-3 or until
                                                  adequate</p> <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e12b856d-7ac1-43f8-88c1-b294d0c3302d"></a><a name="section-8.2"></a><p></p>
<h2>Management of Surgical Procedures <span class="Sup">7-11</span>
</h2>
<p class="First">Dosage guidelines for surgical procedures are suggested
                                    in <a href="#id_933b23b5-2e58-4e84-99d9-6f471d0eb495">Table 4</a>. Administer preoperative loading dose
                                    one hour prior to surgery. Depending on the type of surgery,
                                    continue replacement therapy over one to several weeks until
                                    adequate <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing is achieved. The average treatment
                                    interval will initially be 12 hours, while in the later
                                    postoperative period, 24 hours is adequate.</p>
<a name="id_933b23b5-2e58-4e84-99d9-6f471d0eb495"></a><table border="single" width="536">
<caption><span>Table 4
                                        Management of Surgical Procedures</span></caption>
<col width="11.2%">
<col width="18.5%">
<col width="13.1%">
<col width="18.5%">
<col width="9.1%">
<col width="19.4%">
<col width="10.3%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>N/A–
                                                  Not Applicable.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>For
                                                  patients predisposing to <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> see <span class="Italics">Precautions</span> section.
                                                  </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Type of</span><span class="Bold">Surgery</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">Day of Operation</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Init. Postop.
                                                  Period</span></p>
<span class="Bold">(1st to 2nd
                                                  Week)</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Late Postop.
                                                  Period</span><span class="Bold">(from 3rd Week
                                                  Onwards)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Approx. Level Factor IX </p>
<p>(% Normal)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Dose</p>(IU/kg)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Approx. Level Factor
                                                  IX</p> (% Normal)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Dose</p>(IU/kg)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Approx. Level Factor IX </p>
<p>(% Normal)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Dose</p>(IU/kg)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Minor</span></td>
<td class="Botrule Rrule" align="center" valign="middle"> 40-60</td>
<td class="Botrule Rrule" align="center" valign="middle"> 50-75</td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20-40</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">25-65</p></td>
<td class="Botrule Rrule" align="center" valign="middle">N/A<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">N/A<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Major</span></td>
<td class="Rrule" align="center" valign="middle"><p class="First">≥60<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></p></td>
<td class="Rrule" align="center" valign="middle">
                                                75-90</td>
<td class="Rrule" align="center" valign="middle">20-60</td>
<td class="Rrule" align="center" valign="middle">
                                                25-75</td>
<td class="Rrule" align="center" valign="middle">
                                                20</td>
<td class="Botrule Rrule" align="center" valign="middle"> 25-35 </td>
</tr>
</tbody>
</table>
<p>For tooth extraction, the same initial dose as for minor
                                    surgery is recommended and one infusion should be sufficient. In
                                    case of extraction of several teeth, replacement therapy for up
                                    to one week may be necessary using the same doses as for minor
                                        surgery<span class="Sup">8-11</span>.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_edef72ce-80df-4fad-a10a-f90a8293a197"></a><a name="section-8.3"></a><p></p>
<h2>Reconstitution</h2>
<ul>
<li>Do not mix BEBULIN with other medicinal products or
                                        solvents, other than the enclosed sterilized water for
                                        injection.</li>
<li>Administer BEBULIN within 3 hours after reconstitution as
                                        the solution does not contain a preservative. <span class="Bold">Do not refrigerate after
                                            reconstitution.</span>
</li>
</ul>
<ol>
<li>Warm unopened vials of both diluent and concentrate to
                                        room temperature (not to exceed 37°C, 98°F).</li>
<li>Remove caps from both vials to expose central portions of
                                        the rubber stoppers.</li>
<li>Cleanse exposed surface of the rubber stoppers with
                                        germicidal solution and allow to dry.</li>
<li>Using aseptic technique, remove protective covering from
                                        one end of the double-ended needle and insert the exposed
                                        end through the diluent vial stopper.</li>
<li>Remove protective covering from the other end of the
                                        double-ended needle. Do not touch the exposed end. Invert
                                        diluent vial over the concentrate vial, then insert free end
                                        of the needle through the concentrate vial stopper. Diluent
                                        will be drawn into the concentrate vial by vacuum.</li>
<li>Disconnect the two vials by removing needle from the
                                        concentrate vial stopper. <br>Gently agitate or rotate the
                                        concentrate vial until all material is dissolved.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6027c729-f7cc-4a45-b9dc-ad0940e93a6d"></a><a name="section-8.4"></a><p></p>
<h2>Administration</h2>
<p class="First"><span class="Bold">For Intravenous Administration
                                        Only.</span></p>
<ul>
<li>Parenteral drug products should be inspected for
                                        particulate matter and discoloration prior to
                                        administration. </li>
<li>The reconstituted product should be colorless to slightly
                                        yellowish and clear to slightly turbid solution. Do not
                                        administer if particulate matter or discoloration is found
                                        and notify Baxter immediately.</li>
<li>Record the name of the patient and batch number of the
                                        product in order to maintain a link between the patient and
                                        the batch of the product.</li>
</ul>
<ol>
<li>After reconstituting the concentrate as described above,
                                        attach the enclosed filter needle to a sterile disposable
                                        syringe using aseptic technique. Insert filter needle
                                        through the concentrate vial stopper.</li>
<li>Inject air and withdraw solution into the syringe.</li>
<li>Remove and discard filter needle. Attach a suitable
                                        intravenous needle or infusion set with winged
                                        adapter.</li>
<li>Administer the solution intravenously at a rate
                                        comfortable to the patient. The infusion rate should not
                                        exceed 2 mL per minute.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bcfdc443-cc2c-4805-878d-cd2ef6432179"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">BEBULIN is supplied in single dose vials (NDC 64193-445-02) with
                            Sterile Water for Injection, U.S.P., double-ended needle, and filter
                            needle for reconstitution and withdrawal. Factor IX activity in
                            international units is stated on the label of each vial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4c70e43-8d02-447b-bfec-654355d8db85"></a><a name="section-9.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at refrigerated temperature (2°C-8°C, 35°F-46°F).
                                    Do not use BEBULIN past the expiration date printed on the unit
                                    carton. Do not freeze.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d0c5cf0-e453-4154-af95-305a0820a00a"></a><a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>T. Abe <span class="Italics">et a</span><span class="Italics">l</span>.: Clinical Study with BENOBIL
                                TIM 4, Steam-Treated Factor IX Complex, Single Administration. Jap.
                                Pharm. &amp; Ther., 14, 1986, 1, pp. 19-31.</li>
<li>Vapor Heating is described in: World Health Organization (WHO)
                                Technical Report, Series No. 924, 2004, Annex 4, Guidelines on viral
                                inactivation and removal, procedures intended to assure the viral
                                safety, of human blood plasma products.</li>
<li> D.U. Preiss, B. Eberspächer, D. Abdullah, I. Rosner: Safety of
                                Vapour Heated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Complex Concentrate (PCC) Prothromplex
                                S-TIM4. <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> Research, 63, 1991, pp. 651-659.</li>
<li>I. Warrier: Management of haemophilia B patients with inhibitors
                                and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Haemophilia, 4 (4), pp.574-576.</li>
<li>A. Shapiro, T. Abe, L. M. Aledort, K. Anderle, M. W. Hilgartner,
                                M. Kunschak,<br>F. E. Preston, G. E. Rivard, K. Schimpf and
                                International Factor Safety Study Group: Transfusion, 35, 1995, pp
                                204-208.</li>
<li>Ansell J, Hirsch J, Hylek E, Jacobson A, Crowther M, Palareti G.
                                Pharmacology and management of the vitamin K antagonists: American
                                College of Chest Physicians Evidence-Based Clinical Practice
                                Guidelines (8th ed). Chest 2008, 133:160S-198S.</li>
<li>P. H. Levine: Clinical Manifestations and Therapy of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilias</span> A
                                and B. In: R. W. Colman, J. Hirsh, V. J. Marder, E.W. Salzman
                                (Eds.): Hemostasis and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>. Philadelphia: J. B. Lippincott
                                Company, 1987, pp. 97-111.</li>
<li>C. R. Rizza, P. Jones: Management of patients with inherited blood
                                coagulation defects. In: A.L. Bloom, D.P. Thomas (Eds.): Hemostasis
                                and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>. Edinburgh: Churchill Livingstone, 1987, pp.
                                465-493.</li>
<li>T. Abe, M. Kazama: An International Survey on the Appropriate
                                Dosage of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilias</span> and Related Congenital Coagulopathies. In:
                                Proceedings of the 3rd International Symposium on Haemostasis and
                                <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>, 1982, pp. 273-304.</li>
<li>I. M. Nilsson, Å. Ahlberg, G. Björlin: Clinical Experience with a
                                Swedish Factor IX Concentrate. Acta Med. Scand., 190, 1971, pp.
                                257-266.</li>
<li>J. N. George, R. T. Breckenridge: The Use of Factor VIII and
                                Factor IX Concentrates During Surgery. JAMA, 214, 1970, 9, pp.
                                1673-1676.</li>
</ol>
<p class="First">To enroll in the confidential, Industry-wide Patient Notification
                            System, call 1 888-873-2838.</p>
<p>Baxter and Bebulin are trademarks of Baxter International Inc.,
                            its subsidiaries or affiliates.</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Westlake Village, CA-91362</p>
<p>USA</p>
<p>U.S. License No.
                            140                                            Revised: Jul
                            2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_87f8ab92-4d68-46c7-a159-46f72e148235"></a><a name="section-11"></a><p></p>
<h1>Principle Display Panel</h1>
<div class="Figure">
<img alt=" BEBULIN unit carton for 200-1200 potency ranges" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b375a2fb-7bd4-486c-87f6-72237713d528&amp;name=bc12b9b9-c06d-447f-b08e-77907c357bfd-01.jpg"><p class="MultiMediaCaption">BEBULIN unit
                                carton for 200-1200 potency ranges</p>
</div>
<p class="First">20 mL size, dried</p>
<p>NDC 64193-445-02</p>
<p><span class="Bold">Factor IX Complex</span></p>
<p><span class="Bold">BEBULIN </span></p>
<p><span class="Bold">Nanofiltered and Vapor Heated</span></p>
<p>BAXTER </p>
<p>For Intravenous Use Only</p>
<p><span class="Bold">WARNING</span>: Human plasma
                            product. Human blood and its components may transmit infectious agents.
                            The physician and patient should discuss the risks and benefits of this
                            product.</p>
<p>Some components of the packaging material contain Dry Natural
                            Rubber Latex.</p>
<p><span class="Bold">Rx Only</span></p>
<p>BEBULIN is a trademark of Baxter AG, Vienna, Austria: Baxter is a
                            trademark of Baxter International Inc., registered in the U.S. Patent
                            and Trademark Office.</p>
<div class="Figure">
<img alt="Bebulin Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b375a2fb-7bd4-486c-87f6-72237713d528&amp;name=bc12b9b9-c06d-447f-b08e-77907c357bfd-02.jpg"><p class="MultiMediaCaption">BEBULIN vial label
                                for 200-1200 potency ranges</p>
</div>
<p>20 mL size, dried</p>
<p>NDC 64193-345-01</p>
<p><span class="Bold">Factor IX Complex</span></p>
<p><span class="Bold">BEBULIN </span></p>
<p><span class="Bold">Nanofiltered and Vapor Heated </span></p>
<p>BAXTER </p>
<p>For Intravenous Use Only</p>
<p>Rx Only</p>
<p>Directions for use: see package insert</p>
<p>Store between 2º and 8ºC (35º and 46ºF).</p>
<p>Reconstitute with 20 mL of Sterile Water for
                            Injection</p>
<p>Baxter and Bebulin are trademarks of Baxter International Inc,
                            Its subsidiaries or affiliates</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Westlake Village, CA 91362 USA</p>
<p>U.S. License No. 140</p>
<div class="Figure">
<img alt="20 mL Sterile Water for Injection vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b375a2fb-7bd4-486c-87f6-72237713d528&amp;name=bc12b9b9-c06d-447f-b08e-77907c357bfd-03.jpg"><p class="MultiMediaCaption">20 mL Sterile
                                Water for Injection vial label</p>
</div>
<p>NDC 0338-0764-62</p>
<p>Nonpyrogenic </p>
<p>Single-Dose Container </p>
<p>20 mL</p>
<p><span class="Bold">Sterile Water for Injection, USP for
                                reconstitution of accompanying product</span></p>
<p>Do not use unless clear. No antimicrobial agent or other
                            substances has been added. Do not use for intravascular injection
                            without making approximately isotonic by addition of suitable solute.
                            Discard unused portion. Rx Only. </p>
<p>BAXTER</p>
<p>Manufactured by </p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Deerfield, IL 60015 USA</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BEBULIN 		
					</strong><br><span class="contentTableReg">coagulation factor ix human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64193-445</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64193-445-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">20 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">20 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>BEBULIN 		
					</strong><br><span class="contentTableReg">coagulation factor ix human injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64193-345</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>COAGULATION FACTOR IX HUMAN</strong> (COAGULATION FACTOR IX HUMAN) </td>
<td class="formItem">COAGULATION FACTOR IX HUMAN</td>
<td class="formItem">300 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HEPARIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64193-345-01</td>
<td class="formItem">20 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103112</td>
<td class="formItem">08/19/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0764</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">20 mL  in 20 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0764-62</td>
<td class="formItem">20 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103112</td>
<td class="formItem">08/19/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103112</td>
<td class="formItem">08/19/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(085206634)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">001728059</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bc12b9b9-c06d-447f-b08e-77907c357bfd</div>
<div>Set id: b375a2fb-7bd4-486c-87f6-72237713d528</div>
<div>Version: 7</div>
<div>Effective Time: 20120706</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
